Company intelligence / Profile preview
Placon Therapeutics
Cambridge, Massachusetts, USAbiopharmguy.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Placon Therapeutics has developed BTP‑114, a next-generation platinum-based anticancer agent. Preclinical data showed sustained tumor growth inhibition and reduced dose-limiting toxicities compared to cisplatin. The FDA has accepted the IND for BTP‑114, allowing clinical trials in cancer patients with refractory solid tumors to proceed[2][3][4].
The company seeks strategic partners or investors for further development.
BTP‑114 leverages albumin conjugation for improved tumor targeting and pharmacokinetics[4].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (platinum-based drugs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Placon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Placon Therapeutics.